BRAF and metastatic colorectal cancer: For instance, in a recent clinical trial, the addition of vemurafenib improved the progression-free survival in patients with BRAF-mutant metastatic colorectal cancer treated with irinotecan and cetuximab (Kopetz et al., 2021).